» Articles » PMID: 35493473

Persistence of SARS-CoV-2 Antibodies in Vaccinated Health Care Workers Analyzed by Coronavirus Antigen Microarray

Abstract

Recent studies provide conflicting evidence on the persistence of SARS-CoV-2 immunity induced by mRNA vaccines. Here, we aim to quantify the persistence of humoral immunity following vaccination using a coronavirus antigen microarray that includes 10 SARS-CoV-2 antigens. In a prospective longitudinal cohort of 240 healthcare workers, composite SARS-CoV-2 IgG antibody levels did not wane significantly over a 6-month study period. In the subset of the study population previously exposed to SARS-CoV-2 based on seropositivity for nucleocapsid antibodies, higher composite anti-spike IgG levels were measured before the vaccine but no significant difference from unexposed individuals was observed at 6 months. Age, vaccine type, or worker role did not significantly impact composite IgG levels, although non-significant trends towards lower antibody levels in older participants and higher antibody levels with Moderna vaccine were observed at 6 months. A small subset of our cohort were classified as having waning antibody titers at 6 months, and these individuals were less likely to work in patient care roles and more likely to have prior exposure to SARS-CoV-2.

Citing Articles

Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa, Democratic Republic of Congo: prospective cohort study.

Mukenge E, Sumbu B, Nkodila A, Muwonga J, Makulo J, Ngole M BMC Infect Dis. 2025; 25(1):342.

PMID: 40069636 PMC: 11899428. DOI: 10.1186/s12879-025-10754-4.


Antibody longevity and waning following COVID-19 vaccination in a 1-year longitudinal cohort in Bangladesh.

Haq M, Roy A, Ahmed R, Kuddusi R, Sinha M, Hossain M Sci Rep. 2024; 14(1):11467.

PMID: 38769324 PMC: 11106241. DOI: 10.1038/s41598-024-61922-6.


Machine Learning Classification of Time since BNT162b2 COVID-19 Vaccination Based on Array-Measured Antibody Activity.

Ma Q, Huang F, Guo W, Feng K, Huang T, Cai Y Life (Basel). 2023; 13(6).

PMID: 37374086 PMC: 10305362. DOI: 10.3390/life13061304.


Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population.

Hosseinian S, de Assis R, Khalil G, Luu M, Jain A, Horvath P Front Immunol. 2023; 14:1166261.

PMID: 37266444 PMC: 10229859. DOI: 10.3389/fimmu.2023.1166261.


Analysis and comparison of SARS-CoV-2 variant antibodies and neutralizing activity for 6 months after a booster mRNA vaccine in a healthcare worker population.

Khan S, Hosseinian S, Assis R, Khalil G, Luu M, Jain A Res Sq. 2022; .

PMID: 36561177 PMC: 9774221. DOI: 10.21203/rs.3.rs-2180753/v1.


References
1.
de Assis R, Jain A, Nakajima R, Jasinskas A, Felgner J, Obiero J . Analysis of SARS-CoV-2 antibodies in COVID-19 convalescent blood using a coronavirus antigen microarray. Nat Commun. 2021; 12(1):6. PMC: 7782488. DOI: 10.1038/s41467-020-20095-2. View

2.
Ball C, Brazma A, Causton H, Chervitz S, Edgar R, Hingamp P . Standards for microarray data: an open letter. Environ Health Perspect. 2004; 112(12):A666-7. PMC: 1277123. DOI: 10.1289/ehp.112-1277123. View

3.
Assis R, Jain A, Nakajima R, Jasinskas A, Khan S, Davies H . Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray. Sci Rep. 2021; 11(1):7554. PMC: 8024395. DOI: 10.1038/s41598-021-87137-7. View

4.
Khoury D, Cromer D, Reynaldi A, Schlub T, Wheatley A, Juno J . Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021; 27(7):1205-1211. DOI: 10.1038/s41591-021-01377-8. View

5.
Kohmer N, Westhaus S, Ruhl C, Ciesek S, Rabenau H . Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays. J Clin Virol. 2020; 129:104480. PMC: 7263247. DOI: 10.1016/j.jcv.2020.104480. View